{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:39:55Z","timestamp":1774615195491,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,6,26]],"date-time":"2012-06-26T00:00:00Z","timestamp":1340668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s10620-012-2276-3","type":"journal-article","created":{"date-parts":[[2012,7,10]],"date-time":"2012-07-10T00:11:58Z","timestamp":1341879118000},"page":"2774-2785","source":"Crossref","is-referenced-by-count":35,"title":["Hyponatremia in Cirrhosis and End-Stage Liver Disease: Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan"],"prefix":"10.1007","volume":"57","author":[{"given":"Paul","family":"Gaglio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwaku","family":"Marfo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Joseph","family":"Chiodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,26]]},"reference":[{"key":"2276_CR1","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/hep.510280337","volume":"28","author":"P Gin\u00e8s","year":"1998","unstructured":"Gin\u00e8s P, Berl T, Bernardi M, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology. 1998;28:851\u2013864.","journal-title":"Hepatology"},{"key":"2276_CR2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/0016-5085(88)90441-6","volume":"94","author":"J Llach","year":"1988","unstructured":"Llach J, Gin\u00e8s P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology. 1988;94:482\u2013487.","journal-title":"Gastroenterology"},{"key":"2276_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S0168-8278(00)00011-8","volume":"34","author":"G Fernandez-Esparrach","year":"2001","unstructured":"Fernandez-Esparrach G, Sanchez-Fueyo A, Gin\u00e8s P, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol. 2001;34:46\u201352.","journal-title":"J Hepatol"},{"key":"2276_CR4","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa0801209","volume":"359","author":"WR Kim","year":"2008","unstructured":"Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018\u20131026.","journal-title":"N Engl J Med"},{"key":"2276_CR5","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/hep.21412","volume":"44","author":"P Angeli","year":"2006","unstructured":"Angeli P, Wong F, Watson H, et al. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology. 2006;44:1535\u20131542.","journal-title":"Hepatology"},{"key":"2276_CR6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3904\/kjim.2009.24.2.106","volume":"24","author":"JH Kim","year":"2009","unstructured":"Kim JH, Lee JS, Lee SH, et al. The association between the serum sodium level and the severity of complications in liver cirrhosis. Korean J Intern Med. 2009;24:106\u2013112.","journal-title":"Korean J Intern Med"},{"key":"2276_CR7","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1053\/j.gastro.2006.02.017","volume":"130","author":"M-C Londo\u00f1o","year":"2006","unstructured":"Londo\u00f1o M-C, Guevara M, Rimola A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology. 2006;130:1135\u20131143.","journal-title":"Gastroenterology"},{"key":"2276_CR8","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/j.1478-3231.2009.01982.x","volume":"29","author":"WA Hackworth","year":"2009","unstructured":"Hackworth WA, Heuman DM, Sanyal AJ, et al. Effect of hyponatraemia on outcomes following orthotopic liver transplantation. Liver Int. 2009;29:1071\u20131077.","journal-title":"Liver Int"},{"key":"2276_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1432-2277.2010.01161.x","volume":"24","author":"TJ Weism\u00fcller","year":"2011","unstructured":"Weism\u00fcller TJ, Fikatas P, Schmidt J, et al. Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany\u2014limitations of the \u2018sickest first\u2019 concept. Transpl Int. 2011;24:91\u201399.","journal-title":"Transpl Int"},{"key":"2276_CR10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.amjmed.2007.09.001","volume":"120","author":"JG Verbalis","year":"2007","unstructured":"Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120:S1\u2013S21.","journal-title":"Am J Med"},{"key":"2276_CR11","unstructured":"Otsuka America Pharmaceutical. Samsca\u2122 (tolvaptan) tablets for oral use. Prescribing information. Rockville, MD: Otsuka America Pharmaceutical, Inc., May 2009."},{"key":"2276_CR12","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","volume":"355","author":"RW Schrier","year":"2006","unstructured":"Schrier RW, Gross P, Gheorghiade M, et al. for the SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099\u20132112.","journal-title":"N Engl J Med"},{"key":"2276_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/MCG.0b013e3181aabbcd","volume":"44","author":"C-C Jenq","year":"2010","unstructured":"Jenq C-C, Tsai M-H, Tian Y-C, et al. Serum sodium predicts prognosis in critically ill cirrhotic patients. J Clin Gastroenterol. 2010;44:220\u2013226.","journal-title":"J Clin Gastroenterol"},{"key":"2276_CR14","first-page":"116","volume":"60","author":"S Shaikh","year":"2010","unstructured":"Shaikh S, Mal G, Khalid S, et al. Frequency of hyponatraemia and its influence on liver cirrhosis-related complications. J Pak Med Assoc. 2010;60:116\u2013120.","journal-title":"J Pak Med Assoc"},{"key":"2276_CR15","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1002\/hep.22846","volume":"49","author":"BC Yun","year":"2009","unstructured":"Yun BC, Kim WR, Benson JT, et al. Impact of pretransplant hyponatremia on outcome following liver transplantation. Hepatology. 2009;49:1610\u20131615.","journal-title":"Hepatology"},{"key":"2276_CR16","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.cgh.2006.08.007","volume":"4","author":"R Planas","year":"2006","unstructured":"Planas R, Montoliu S, Ballest\u00e9 B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1386\u20131394.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2276_CR17","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/ajg.2009.293","volume":"104","author":"M Guevara","year":"2009","unstructured":"Guevara M, Baccaro ME, Torre A, et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol. 2009;104:1382\u20131389.","journal-title":"Am J Gastroenterol"},{"key":"2276_CR18","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1111\/j.1478-3231.2010.02293.x","volume":"30","author":"M Guevara","year":"2010","unstructured":"Guevara M, Baccaro ME, Rios J, et al. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int. 2010;30:1137\u20131142.","journal-title":"Liver Int"},{"key":"2276_CR19","first-page":"728","volume-title":"Text Book of Hepatology. From Basic Science to Clinical Practise","author":"D Haussinger","year":"2007","unstructured":"Haussinger D, Blei AT. Hepatic encephalopathy. In: Rodes J, Benhamou JP, Blei AT, Reichen J, Rizzetto M, eds. Text Book of Hepatology. From Basic Science to Clinical Practise. Oxford: Blackwell; 2007:728\u2013760."},{"key":"2276_CR20","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/hep.1840400409","volume":"40","author":"DM Heuman","year":"2004","unstructured":"Heuman DM, Abou-assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004;40:802\u2013810.","journal-title":"Hepatology"},{"key":"2276_CR21","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1016\/j.transproceed.2010.10.019","volume":"42","author":"IFSF Boin","year":"2010","unstructured":"Boin IFSF, Capel C Jr, Ataide EC, et al. Pretransplant hyponatremia could be associated with a poor prognosis after liver transplantation. Transpl Proc. 2010;42:4119\u20134122.","journal-title":"Transpl Proc"},{"key":"2276_CR22","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/j.1440-1746.2009.06162.x","volume":"25","author":"T Fukuhara","year":"2010","unstructured":"Fukuhara T, Ikegami T, Morita K, et al. Impact of preoperative serum sodium concentration in living donor liver transplantation. J Gastroenterol Hepatol. 2010;25:978\u2013984.","journal-title":"J Gastroenterol Hepatol"},{"key":"2276_CR23","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1053\/j.gastro.2006.02.010","volume":"130","author":"SW Biggins","year":"2006","unstructured":"Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130:1652\u20131660.","journal-title":"Gastroenterology"},{"key":"2276_CR24","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/lt.20329","volume":"11","author":"AE Ruf","year":"2005","unstructured":"Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005;11:336\u2013343.","journal-title":"Liver Transpl"},{"key":"2276_CR25","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM200005253422107","volume":"342","author":"HJ Adrogu\u00e9","year":"2000","unstructured":"Adrogu\u00e9 HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581\u20131589.","journal-title":"N Engl J Med"},{"key":"2276_CR26","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.3949\/ccjm.73.Suppl_3.S4","volume":"73","author":"I Douglas","year":"2006","unstructured":"Douglas I. Hyponatremia: why it matters, how it presents, how we can manage it. Cleve Clin J Med. 2006;73:S4\u2013S12.","journal-title":"Cleve Clin J Med"},{"key":"2276_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3810\/hp.2010.02.283","volume":"38","author":"RD Zenenberg","year":"2010","unstructured":"Zenenberg RD, Carluccio AL, Merlin MA. Hyponatremia: evaluation and management. Hosp Pract (Minneap). 2010;38:89\u201396.","journal-title":"Hosp Pract (Minneap)"},{"key":"2276_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1445-5994.2006.01294.x","volume":"37","author":"M Bissram","year":"2007","unstructured":"Bissram M, Scott FD, Liu L, Rosner MH. Risk factors for symptomatic hyponatraemia: the role of pre-existing asymptomatic hyponatraemia. Intern Med J. 2007;37:149\u2013155.","journal-title":"Intern Med J"},{"key":"2276_CR29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.semnephrol.2009.03.002","volume":"29","author":"RH Sterns","year":"2009","unstructured":"Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol. 2009;29:282\u2013299.","journal-title":"Semin Nephrol"},{"key":"2276_CR30","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1681\/ASN.V481522","volume":"4","author":"RH Sterns","year":"1994","unstructured":"Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol. 1994;4:1522\u20131530.","journal-title":"J Am Soc Nephrol"},{"key":"2276_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3810\/hp.2009.12.266","volume":"37","author":"T Vu","year":"2009","unstructured":"Vu T, Wong R, Hamblin PS, Zajac J, Grossman M. Patients presenting with severe hypotonic hyponatremia: etiologic factors, assessment, and outcomes. Hosp Pract (Minneap). 2009;37:128\u2013136.","journal-title":"Hosp Pract (Minneap)"},{"key":"2276_CR32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3949\/ccjm.77a.08051","volume":"77","author":"C Vaidya","year":"2010","unstructured":"Vaidya C, Ho W, Freda BJ. Management of hyponatremia: providing treatment and avoiding harm. Cleve Clin J Med. 2010;77:715\u2013726.","journal-title":"Cleve Clin J Med"},{"key":"2276_CR33","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/0002-9343(57)90224-3","volume":"23","author":"WB Schwartz","year":"1957","unstructured":"Schwartz WB, Bennet W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med. 1957;23:529\u2013542.","journal-title":"Am J Med"},{"key":"2276_CR34","doi-asserted-by":"publisher","first-page":"232A","DOI":"10.1016\/S0168-8278(07)61830-3","volume":"46","author":"R Jalan","year":"2007","unstructured":"Jalan R, Mookerjee R, Cheshire L, Williams R, Davies N. Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial. J Hepatol. 2007;46:232A.","journal-title":"J Hepatol"},{"key":"2276_CR35","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1136\/gut.31.2.204","volume":"31","author":"PA McCormick","year":"1990","unstructured":"McCormick PA, Mistry P, Kaye G, Burroughs AK, McIntyre N. Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites. Gut. 1990;31:204\u2013207.","journal-title":"Gut"},{"key":"2276_CR36","unstructured":"Astellas Pharma US. Vaprisol\u00ae (conivaptan hydrochloride) injection for intravenous use. Prescribing information. Deerfield, IL: Astellas Pharma US, Inc.; February 2011."},{"key":"2276_CR37","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1159\/000106456","volume":"27","author":"D Zeltser","year":"2007","unstructured":"Zeltser D, Rosansky S, van Rensburg H, et al. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol. 2007;27:447\u2013457.","journal-title":"Am J Nephrol"},{"key":"2276_CR38","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/lt.21836","volume":"15","author":"JG O\u2019Leary","year":"2009","unstructured":"O\u2019Leary JG, Davis GL. Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease. Liver Transpl. 2009;15:1325\u20131329.","journal-title":"Liver Transpl"},{"key":"2276_CR39","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2165\/00003495-200767060-00002","volume":"67","author":"F Ali","year":"2007","unstructured":"Ali F, Guglin M, Vaitkevicius P, et al. Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67:847\u2013858.","journal-title":"Drugs"},{"key":"2276_CR40","unstructured":"Murry L (ed). Red Book\u00ae: Pharmacy\u2019s Fundamental Reference. August Update, 2009 Edition. Montvale, NJ; Department of Pharmacy Services, University of Utah, 2009."},{"key":"2276_CR41","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/jhep.2002.36375","volume":"36","author":"D Guyader","year":"2002","unstructured":"Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology. 2002;36:1197\u20131205.","journal-title":"Hepatology"},{"key":"2276_CR42","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1053\/jhep.2003.50021","volume":"37","author":"F Wong","year":"2003","unstructured":"Wong F, Blei AT, Blendis LM, et al. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003;37:182\u2013191.","journal-title":"Hepatology"},{"key":"2276_CR43","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1053\/gast.2003.50143","volume":"124","author":"AL Gerbes","year":"2003","unstructured":"Gerbes AL, G\u00fclberg V, Gin\u00e8s P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003;124:933\u2013939.","journal-title":"Gastroenterology"},{"key":"2276_CR44","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/hep.22293","volume":"48","author":"P Gin\u00e8s","year":"2008","unstructured":"Gin\u00e8s P, Wong F, Watson H, et al. Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008;48:204\u2013213.","journal-title":"Hepatology"},{"key":"2276_CR45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/gutjnl-2011-300157","volume":"61","author":"F Wong","year":"2012","unstructured":"Wong F, Watson H, Gerbes A, et al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut. 2012;61:108\u2013116.","journal-title":"Gut"},{"key":"2276_CR46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jhep.2010.02.036","volume":"53","author":"F Wong","year":"2010","unstructured":"Wong F, Gines P, Watson H, et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol. 2010;53:283\u2013290.","journal-title":"J Hepatol"},{"key":"2276_CR47","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.amjcard.2005.10.050","volume":"97","author":"M Gheorghiade","year":"2006","unstructured":"Gheorghiade M, Gottlieb SS, Udelson JE, et al. Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol. 2006;97:1064\u20131067.","journal-title":"Am J Cardiol"},{"key":"2276_CR48","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00535-010-0240-6","volume":"45","author":"K Okita","year":"2010","unstructured":"Okita K, Sakaida I, Okada M, et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol. 2010;45:979\u2013987.","journal-title":"J Gastroenterol"},{"key":"2276_CR49","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.jhep.2011.08.020","volume":"56","author":"A C\u00e1rdenas","year":"2012","unstructured":"C\u00e1rdenas A, Gin\u00e8s P, Marotta P, et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol. 2012;56:571\u2013578.","journal-title":"J Hepatol"},{"key":"2276_CR50","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1681\/ASN.2009080857","volume":"21","author":"T Berl","year":"2010","unstructured":"Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21:705\u2013712.","journal-title":"J Am Soc Nephrol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2276-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-012-2276-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2276-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2276-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T19:01:50Z","timestamp":1642705310000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-012-2276-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,26]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["2276"],"URL":"https:\/\/doi.org\/10.1007\/s10620-012-2276-3","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,26]]}}}